Boehringer Ingelheim  Boehringer Ingelheim

Release Summary

U.S. FDA approves Jardiance® (empagliflozin) tablets to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease

Boehringer Ingelheim